- Home
- SILC vs ZNTL Comparison
SILC vs ZNTL Comparison
Compare SILC & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- ZNTL
- Stock Information
- Founded
- SILC 1987
- ZNTL 2014
- Country
- SILC Israel
- ZNTL United States
- Employees
- SILC N/A
- ZNTL N/A
- Industry
- SILC Computer Manufacturing
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- SILC Technology
- ZNTL Health Care
- Exchange
- SILC Nasdaq
- ZNTL Nasdaq
- Market Cap
- SILC 99.6M
- ZNTL 118.3M
- IPO Year
- SILC 1994
- ZNTL 2020
- Fundamental
- Price
- SILC $14.04
- ZNTL $1.34
- Analyst Decision
- SILC Hold
- ZNTL Buy
- Analyst Count
- SILC 1
- ZNTL 7
- Target Price
- SILC N/A
- ZNTL $6.17
- AVG Volume (30 Days)
- SILC 27.7K
- ZNTL 702.2K
- Earning Date
- SILC 10-30-2025
- ZNTL 11-10-2025
- Dividend Yield
- SILC N/A
- ZNTL N/A
- EPS Growth
- SILC N/A
- ZNTL N/A
- EPS
- SILC N/A
- ZNTL N/A
- Revenue
- SILC $59,509,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- SILC $6.48
- ZNTL N/A
- Revenue Next Year
- SILC $14.36
- ZNTL N/A
- P/E Ratio
- SILC N/A
- ZNTL N/A
- Revenue Growth
- SILC N/A
- ZNTL N/A
- 52 Week Low
- SILC $12.29
- ZNTL $1.01
- 52 Week High
- SILC $19.37
- ZNTL $4.16
- Technical
- Relative Strength Index (RSI)
- SILC 39.10
- ZNTL 40.42
- Support Level
- SILC $14.60
- ZNTL $1.25
- Resistance Level
- SILC $15.23
- ZNTL $1.41
- Average True Range (ATR)
- SILC 0.82
- ZNTL 0.10
- MACD
- SILC -0.19
- ZNTL -0.01
- Stochastic Oscillator
- SILC 22.60
- ZNTL 22.04
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.